Revised forecast
Fiscal year ending October 2026 · Second quarter (interim period)Previous forecast published 12 December 2025The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
Net sales are expected to exceed the previous forecast because shipments of generic versions of Axive were brought forward as part of sales promotion ahead of entry into the U.S. market, and sales in the Chemicals business have been strong. Profit is expected to increase because of higher sales and profit secured through the earlier-than-planned shipments of Axive.
The Company expects to record extraordinary losses, including impairment losses and structural reform expenses. Amount: Not disclosed.
| Item | Details |
|---|---|
| Net Sales | ¥92,800 million → ¥102,900 million（+10.9%） |
| Operating profit | ¥6,100 million → ¥10,400 million（+70.5%） |
| Ordinary income | ¥8,200 million → ¥13,700 million（+67.1%） |
| Profit attributable to owners of the parent | ¥4,400 million → ¥8,700 million（+97.7%） |
| Net income per share | 36.54 yen and sen → 72.24 yen and sen |
| Fiscal Period Covered | Fiscal year ending October 2026 |
| Period Covered | Second quarter (interim period) |
| Publication date of previous forecast | 12 December 2025 |
| Previous-period results | Net sales: ¥96,177 million; operating income: ¥9,442 million; ordinary income: ¥8,291 million; interim net income attributable to owners of the parent: ¥6,274 million; interim net income per share: ¥52.11 (fiscal year ended October 2025) |
| Reason for the revision | Net sales are expected to exceed the previous forecast because shipments of generic versions of Axive were brought forward as part of sales promotion ahead of entry into the U.S. market, and sales in the Chemicals business have been strong. Profit is expected to increase because of higher sales and profit secured through the earlier-than-planned shipments of Axive. |
| Details and amount of extraordinary loss | The Company expects to record extraordinary losses, including impairment losses and structural reform expenses. Amount: Not disclosed. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (1)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Shipments of generic versions of Axive were brought forward as part of sales promotion ahead of entry into the U.S. market, and sales in the Chemicals business have remained strong, so net sales are expected to exceed the previous forecast. Profit is expected to increase because of higher sales and profit secured through the earlier-than-planned shipments of Axive. Although the Company expects to record extraordinary losses, including impairment losses and structural reform expenses, interim net income is also expected to increase. The full-year forecasts remain unchanged because the impact of the escalating situation in the Middle East and the prolonged conflict is still being examined in detail.